Hot Features
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloido... Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.74 | -8.39002267574 | 8.82 | 9.59 | 7.91 | 1162616 | 8.6709334 | CS |
| 4 | -1.29 | -13.7673425827 | 9.37 | 10.77 | 7.91 | 1440944 | 8.96511063 | CS |
| 12 | -2.12 | -20.7843137255 | 10.2 | 11.6099 | 7.91 | 982492 | 9.22361163 | CS |
| 26 | 3.15 | 63.8945233266 | 4.93 | 11.6099 | 4.18 | 1014305 | 7.68497942 | CS |
| 52 | 6 | 288.461538462 | 2.08 | 11.6099 | 1.94 | 692749 | 6.41732791 | CS |
| 156 | 5.99 | 286.602870813 | 2.09 | 11.6099 | 1.26 | 354210 | 5.23906331 | CS |
| 260 | 3.08 | 61.6 | 5 | 11.6099 | 0.68 | 825232 | 4.4858087 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.